Skye Bioscience, Inc.
SKYE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.04 | 0.01 | -0.00 | 0.09 |
| FCF Yield | -25.99% | -73.28% | -160.94% | -31.06% |
| EV / EBITDA | -1.38 | -0.61 | -0.47 | -1.85 |
| Quality | ||||
| ROIC | -53.12% | -550.58% | 1,180.87% | -98.12% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.95 | 0.37 | 0.65 | 0.76 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -92.21% | -9.34% | -94.53% | -8.32% |
| Safety | ||||
| Net Debt / EBITDA | 2.66 | -0.09 | -0.04 | 0.89 |
| Interest Coverage | -48.61 | -15.09 | -18.20 | -10.20 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -695.74 | -3,395.24 | -5,696.95 | -9,624.79 |